Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
272lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Learning paths
Pick a track — progress rings update as you complete lessons.
43 lessons
9mPeptidesIntermediate
Why Tissue Repair Keeps Showing Up in Peptide Research
Tissue repair is not a side topic anymore. It is one of the clearest signals in peptide research, from wound care to training recovery.
8mPeptidesIntermediate
Copper Peptides and Diabetic Wounds: What the New Hydrogel Study Actually Suggests
Copper peptide chemistry is getting more interesting because the newest diabetic wound work tries to solve glucose, hypoxia, and infection in the same system.
9mPeptidesIntermediate
GLP-1s, Sleep, and Mood: The Tradeoffs Most People Miss
GLP-1s can change sleep and mood in both directions. The pattern usually comes down to dose timing, appetite changes, side effects, and the bigger metabolic picture.
9mPeptidesIntermediate
Tesamorelin's Clinical Utility: Why Waist, Liver Fat, and IGF-1 Belong Together
Tesamorelin makes more sense when you track the body it changes, not just the number on the scale. Waist, liver fat, IGF-1, and lean mass tell the real story.
10mPeptidesIntermediate
Peptide Research Signals for August 19, 2026: What Changed for Retatrutide, BPC-157, GHK-Cu, and MOTS-C
This week’s signal is less about hype and more about discipline. The compounds matter, but the outcome depends on what you track when appetite, recovery, and tissue repair start to change.
8mPeptidesIntermediate
How GLP-1 Receptor Agonists Change Appetite and Energy Regulation
GLP-1 drugs do more than blunt hunger. They change the signals that shape appetite, food reward, and energy balance, which is why the mechanism matters.
9mPeptidesIntermediate
Pemvidutide, MASH, and the Liver-Waist Signal: Why Weight Loss Alone Misses the Point
Pemvidutide is interesting because it does not just ask whether body weight falls. It asks whether liver fat, waist size, appetite, and recovery move together in a clean direction.
9mPeptidesIntermediate
August 14, 2026 Peptide Research Signals: What to Watch Next
The newest peptide research batch is less about hype and more about the questions each compound answers. Retatrutide, tesamorelin, BPC-157, GHK-Cu, and MOTS-C all point at different tracking priorities.
8mPeptidesIntermediate
The 2026 Peptide Shift: Why Recovery Is Beating the Scale
The new peptide conversation is not just about appetite and fat loss. Recovery, tissue quality, and mitochondrial support are becoming the real filters.
9mPeptidesIntermediate
GLP-1 Adherence Starts With Perceived Competence: Why the Best Plans Feel Simple
People do not stay on GLP-1 plans because they are disciplined forever. They stay on them when the plan feels manageable, repeatable, and clear enough to trust on a busy week.
9mPeptidesIntermediate
August 2026 Peptide Research Roundup: What Changed for Retatrutide, BPC-157, MOTS-c, and GHK-Cu
The latest peptide research wave is less about hype and more about what survives real-world tracking. Here is the practical read on retatrutide, BPC-157, MOTS-c, and GHK-Cu.
9mPeptidesIntermediate
MOTS-C and the Recovery Gap: Why Better Signaling Does Not Automatically Mean Better Recovery
MOTS-C keeps showing up in 2026 because it points at mitochondrial signaling. The trap is assuming that better signaling automatically means better recovery. It does not.
9mPeptidesIntermediate
Retatrutide and the Recovery Tax: Why Appetite Suppression Can Quietly Hurt Results
The hard part of retatrutide is not the first week. It is what happens when appetite falls faster than planning improves. Protein, training, and sleep start to pay the bill.
8mPeptidesIntermediate
August 2026 Peptide Research Snapshot: Recovery, GLP-1, Collagen, and Mitochondria
The clearest signal in today's peptide research is not one molecule. It is the pattern: recovery peptides, metabolic peptides, collagen support, and mitochondrial tools all need tighter tracking.
9mPeptidesIntermediate
Eloralintide Beginner's Guide: What LY3841136 Is and Why Amylin Matters
Eloralintide is Lilly's once-weekly selective amylin receptor agonist. If you follow GLP-1s, CagriSema, or retatrutide, this is the next pathway to understand — satiety biology, trial doses, and what the early data actually show.
8mPeptidesIntermediate
BPC-157 Safety in 2026: What the Evidence Actually Says About Recovery and Risk
BPC-157 has a real research footprint, but most of the confidence in the compound still comes from preclinical work. That gap matters when people start talking about safety like the answer is settled.
8mPeptidesIntermediate
GHK-Cu and Collagen Repair: What the Research Suggests
GHK-Cu is not a magic skin fix. It is a copper peptide with a real research trail behind collagen support, tissue remodeling, and wound healing.
8mPeptidesIntermediate
Retatrutide, Heat, and the Side-Effect Story: What the New Data Means
Retatrutide's hype is not just about weight loss. The bigger story is the way a triple agonist can feel different, from warmth and energy expenditure to the GI side effects that shape adherence.
9mPeptidesIntermediate
The 2026 Peptide Research Signal Map: 5 Themes That Keep Reappearing
The peptide conversation is crowded. The useful question is which signals keep showing up in the data and which ones are still mostly hype.
9mPeptidesIntermediate
MOTS-C in July 2026: The FDA Review, Human Data, and What to Track
MOTS-C sits at the intersection of mitochondrial signaling, metabolism, and longevity. July 2026 put it back in the spotlight for a reason.
8mPeptidesIntermediate
July 2026 Peptide Research Snapshot: Retatrutide, BPC-157, MOTS-C, GHK-Cu, and Tesamorelin
The peptide space is loud. This snapshot cuts through the noise and focuses on the compounds that still have real biology behind them.
8mPeptidesIntermediate
MOTS-C and Human Mesenchymal Stromal Cells: The Tradeoff Nobody Wanted to Miss
MOTS-C may help metabolic signaling in human cells, but the same signal could come with a repair cost. That matters for anyone reading the longevity hype.
10mPeptidesIntermediate
July 2026 Peptide Research Signals: The 5 Compounds Worth Watching
The most useful peptide research is not the loudest. It is the stuff that changes the question from 'does it work?' to 'who does it help, for what outcome, and with what tradeoffs?'
9mPeptidesIntermediate
Therapeutic Peptides in Gerontology: What Healthy Aging Research Actually Shows
Healthy aging is not a slogan. It is a measurable question about inflammation, tissue repair, metabolic control, and whether a peptide has human data behind it.
9mPeptidesIntermediate
What Real-World GLP-1 Data Actually Tells Us About Safety and Results
Clinical trials show the headline results. Real-world data shows what happens after the first prescription, after the side effects, and after people try to stay on therapy long enough to benefit.
8mPeptidesIntermediate
GLP-1s, Delayed Gastric Emptying, and Surgery: What the Perioperative Debate Means
GLP-1s can slow gastric emptying, which is why surgery teams now ask different questions. The key is to understand the risk without turning it into fear or hype.
9mPeptidesIntermediate
GHK-Cu, Collagen, and Tissue Remodeling: What the Research Actually Suggests
GHK-Cu is more than a cosmetic peptide. The interesting signal is tissue remodeling, matrix repair, and how that may matter for skin, hair, and recovery.
9mPeptidesIntermediate
Retatrutide and Chronic Kidney Disease: What the 2026 Meta-Analysis Adds
Retatrutide is no longer just a weight-loss story. The latest kidney-aware review sharpens the question: which metabolic patients need tighter monitoring, slower escalation, and better data?
8mPeptidesIntermediate
MOTS-c and Cardiac Ischemia-Reperfusion: What the New Rat-Heart Study Shows
MOTS-c is showing up in cardiac stress research. A new rat-heart study points toward mitochondrial bioenergetics, mtDNA integrity, and post-ischemic recovery.
8mPeptidesIntermediate
MOTS-c and Inflammatory Lung Disease: What the New Research Suggests
MOTS-c is moving beyond generic energy claims. New research points toward mitochondrial stress response, lung inflammation, and cardiac reperfusion biology.
8mPeptidesIntermediate
GLP-1s and Biological Aging: What the New Semaglutide Study Shows
GLP-1 research is moving into healthspan and epigenetic aging. The new semaglutide signal is worth tracking, but it is not proof of age reversal.
8mPeptidesIntermediate
MOTS-c and Soft Tissue Survival: What the New Autophagy Study Suggests
MOTS-c is being studied beyond energy and metabolism. New research points toward tissue-stress biology, lysosomal stability, and cell survival under ischemic pressure.
8mPeptidesIntermediate
GLP-1s and Breast Cancer Risk: What the New Signal Means
GLP-1 research is moving beyond weight loss. New breast cancer risk and survival signals are interesting, but they need careful interpretation.
8mPeptidesIntermediate
Amylin and GLP-1: The Next Wave of Metabolic Peptides
The next metabolic peptide wave is not just stronger GLP-1 dosing. Amylin, GIP, glucagon, and combination protocols are changing what serious tracking should include.
7mPeptidesIntermediate
CagriSema and Amylin: Why GLP-1 Stacks Are Changing in 2026
GLP-1 therapy is no longer just GLP-1. CagriSema, cagrilintide, petrelintide, and amycretin show why amylin is becoming a serious metabolic target.
8mResearchAdvanced
Peptide Clinical Evidence in 2026: How to Separate Signal from Hype
Peptide research is moving fast. Here is how to read the evidence before turning a headline, mechanism, or social post into a protocol.
8mPeptidesIntermediate
MOTS-c and Arterial Stiffness: What the 2026 Pilot Study Shows
A new MOTS-c pilot study adds a vascular-health signal to the mitochondrial peptide conversation, but it should be read as biomarker research, not a protocol claim.
7mPeptidesIntermediate
Dapiglutide: What the GLP-1/GLP-2 Obesity Trial Means
Dapiglutide is not another simple GLP-1 copycat. The early 2026 trial missed statistical significance for weight loss, but the mechanism points toward the next phase of peptide design.
8mPeptidesIntermediate
GHK-Cu vs Minoxidil: The Copper Peptide That Outperformed the #1 Hair Loss Treatment
Most people fighting hair loss default to minoxidil. But a 2022 clinical trial showed a 0.5% GHK-Cu serum increased hair count by 22% over 16 weeks — beating 3% minoxidil. And GHK-Cu doesn't just grow hair. It works at the genomic level.
9mPeptidesIntermediate
GHK-Cu and Cognitive Aging: New Research on the Copper Peptide's Brain Benefits
GHK-Cu has long been known for its skin and healing benefits. A fresh April 2026 preprint adds a surprising new dimension — cognitive aging reversal in mouse models via BDNF upregulation and neuroinflammation suppression.
14mPeptidesAdvanced
Peptides for Longevity: The Emerging Science Behind Age-Reversal Compounds
The peptide space is shifting from weight loss toward longevity. Explore the science behind peptides designed to slow aging, repair cellular damage, and extend healthspan.
10mPeptidesIntermediate
Latest Peptide Research Breakthroughs: What's Coming in 2026
The peptide space is evolving rapidly. Here's what researchers are discovering, which new compounds show promise, and what breakthroughs could hit the market soon.
10mResearchAdvanced
How to Read Peptide Research: Understanding Studies and Claims
Develop the skills to critically evaluate peptide research and distinguish solid science from marketing hype.
Also available at /blog for legacy links.